Simultaneous MRI diffusion and perfusion imaging for tumor delineation in prostate cancer patients

Radiotherapy and Oncology

Volumn 95, Issue 2, 2010, Pages 185-190

  Groenendaal, Greetje ^a   Van Den Berg, Cornelis A T ^a   Korporaal, Jan G ^a   Philippens, Marielle E P ^a   Luijten, Peter R ^a   Van Vulpen, Marco ^a   Van Der Heide, Uulke A ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

DCE MRI; DWI; Prostate; Tumor delineation

Indexed keywords

GADOBUTROL; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER PATIENT; CANCER STAGING; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; DIFFUSION WEIGHTED IMAGING; GLEASON SCORE; HUMAN; IMAGING AND DISPLAY; KNOWLEDGE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RADIATION DOSE; RECEIVER OPERATING CHARACTERISTIC; SCINTIGRAPHY; VOXEL BASED MORPHOMETRY; COMPARATIVE STUDY; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR;

AGED; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 77956607093     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2010.02.014     Document Type: Article

References (40)

1. Peeters STH, Heemsbergen WD, Koper PCM, et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 2006;24:1990-6. (Pubitemid 46622106)
2. Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002;53:1097-105. (Pubitemid 34787842)
3. Zietman AL, DeSilvio ML, Slater JD, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 2005;294:1233-9. (Pubitemid 41352111)
4. Al-Mamgani A, Van Putten WLJ, Heemsbergen WD, et al. Update of dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008;72:980-8.
5. Cellini N, Morganti AG, Mattiucci GC, et al. Analysis of intraprostatic failures in patients treated with hormonal therapy and radiotherapy: implications for conformal therapy planning. Int J Radiat Oncol Biol Phys 2002;53:595-9. (Pubitemid 34626498)
6. Pucar D, Hricak H, Shukla-Dave A, et al. Clinically significant prostate cancer local recurrence after radiation therapy occurs at the site of primary tumor: magnetic resonance imaging and step-section pathology evidence. Int J Radiat Oncol Biol Phys 2007;69:62-9. (Pubitemid 47247515)
7. Pickett B, Vigneault E, Kurhanewicz J, Verhey L, Roach M. Static field intensity modulation to treat a dominant intra-prostatic lesion to 90 Gy compared to seven field 3-dimensional radiotherapy. Int J Radiat Oncol Biol Phys 1999;43:921-9. (Pubitemid 29284143)
8. Van Lin ENJT, Fütterer JJ, Heijmink SWTPJ, et al. IMRT boost dose planning on dominant intraprostatic lesions: gold marker-based three-dimensional fusion of CT with dynamic contrast-enhanced and 1H-spectroscopic MRI. Int J Radiat Oncol Biol Phys 2006;65:291-303.
9. Singh AK, Guion P, Sears-Crouse N, et al. Simultaneous integrated boost of biopsy proven, MRI defined dominant intra-prostatic lesions to 95 Gray with IMRT: early results of a phase I NCI study. Radiat Oncol 2007;2:36.
10. Miao H, Fukatsu H, Ishigaki T. Prostate cancer detection with 3-T MRI: comparison of diffusion-weighted and T2-weighted imaging. Eur J Radiol 2007;61:297-302. (Pubitemid 46096691)
11. Padhani AR, Gapinski CJ, Macvicar DA, et al. Dynamic contrast enhanced MRI of prostate cancer: correlation with morphology and tumour stage, histological grade and PSA. Clin Radiol 2000;55:99-109. (Pubitemid 32054531)
12. White S, Hricak H, Forstner R, et al. Prostate cancer: effect of postbiopsy hemorrhage on interpretation of MR images. Radiology 1995;195:385-90.
13. Scheidler J, Hricak H, Vigneron DB, et al. Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging - clinicopathologic study. RAD 1999;213:473-80. (Pubitemid 29510595)
14. Van Dorsten FA, van der Graaf M, Engelbrecht MRW, et al. Combined quantitative dynamic contrast-enhanced MR imaging an 1H NMR spectroscopic imaging of human prostate cancer. J Magn Reson Imaging 2004;20:279-87. (Pubitemid 38970937)
15. Fütterer JJ, Heijmink SWTPJ, Scheenen TWJ, et al. Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology 2006;241:449-58. (Pubitemid 44632891)
16. Hosseinzadeh K, Schwarz SD. Endorectal diffusion-weighted imaging in prostate cancer to differentiate malignant and benign peripheral zone tissue. J Magn Reson Imaging 2004;20:654-61. (Pubitemid 39313742)
17. Sato C, Naganawa S, Nakamura T, et al. Differentiation of noncancerous tissue and cancer lesions by apparent diffusion coefficient values in transition and peripheral zones of the prostate. J Magn Reson Imaging 2005;21:258-62. (Pubitemid 40280120)
18. Pickles MD, Gibbs P, Sreenivas M, Turnbull LW. Diffusion-weighted imaging of normal and malignant prostate tissue at 3.0 T. J Magn Reson Imaging 2006;23:130-4. (Pubitemid 43191065)
19. Gibbs P, Pickles MD, Turnbull LW. Diffusion imaging of the prostate at 3.0 tesla. Invest Radiol 2006;41:185-8. (Pubitemid 44406217)
20. Kumar V, Jagannathan NR, R K, et al. Apparent diffusion coefficient of the prostate in men prior to biopsy: determination of a cut-off value to predict malignancy of the peripheral zone. NMR Biomed 2007;20:505-11. (Pubitemid 47272370)
21. Haider MA, van der Kwast TH, Tanguay J, et al. Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer. Am J Roentgenol 2007;189:323-8. (Pubitemid 47195916)
22. Padhani AR. Dynamic contrast-enhanced mr in clinical oncology: current status and future directions. J Magn Reson Imaging 2002;16:407-22. (Pubitemid 35167876)
23. Buckley DL, Roberts C, Parker GJM, Logue JP, Hutchinson CE. Prostate cancer: evaluation of vascular characteristics with dynamic contrast-enhanced T1- weighted MR imaging - initial experience. Radiology 2004;233:709-15.
24. Kozlowski P, Chang SD, Jones EC, Berean KW, Chen H, Goldenberg SL. Combined diffusion-weighted and dynamic contrast-enhanced MRI for prostate cancer diagnosis-correlation with biopsy and histopathology. J Magn Reson Imaging 2006;24:108-13.
25. Franiel T, Lüdemann L, Rudolph B, et al. Evaluation of normal prostate tissue, chronic prostatitis, and prostate cancer by quantitative perfusion analysis using a dynamic contrast-enhanced inversion-prepared dual-contrast gradient echo sequence. Invest Radiol 2008;43:481-7.
26. Ocak I, Bernardo M, Metzger G, et al. Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters. Am J Roentgenol 2007;189:849.
27. Padhani AR, Liu G, Koh DM, et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 2009;11:102-25.
28. Pauls S, Mottaghy FM, Schmidt SA, et al. Evaluation of lung tumor perfusion by dynamic contrast-enhanced MRI. MRI 2008;26:1334-41.
29. Palmowski M, Schifferdecker I, Zwick S, et al. Tumor perfusion assessed by dynamic contrast-enhanced MRI correlates to the grading of renal cell carcinoma: initial results. EJR 2009.
30. Fram EK, Herfkens RJ, Johnson GA, et al. Rapid calculation of T1 using variable flip angle gradient refocused imaging. Magn Reson Med 1987;5:201-8. (Pubitemid 17133355)
31. Klein S, Staring M, Murphy K, Viergever MA, Pluim JPW. Elastix: a toolbox for intensity-based medical image registration. IEEE Trans Med Imaging; in press.
32. Rohrer M, Bauer H, Mintorovitch J, Requardt M, Weinmann HJ. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. IR 2005;40:715-24. (Pubitemid 41546838)
33. Tofts PS, Brix G, Buckley DL, et al. Estimating kinetic parameters from dynamic contrast-enhanced T1-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999;10:223-32. (Pubitemid 29463104)
34. Murase K. Efficient method for calculating kinetic parameters using T1- weighted dynamic contrast-enhanced magnetic resonance imaging. Magn Reson Med 2004;51:858-62. (Pubitemid 38420465)
35. Norris DG, Niendorf T. Interpretation of DW-NMR data: dependence on experimental conditions. NMRBio 1995;8:280-8.
36. Langer DL, Van der Kwast TH, Evans AJ, et al. Intermixed normal tissue within prostate cancer: effect on MR imaging measurements of apparent diffusion coefficient and T2-sparse versus dense cancers. Radiology 2008;249:900-8.
37. Park H, Piert MR, Khan A, et al. Registration methodology for histological sections and in vivo imaging of human prostate. AR 2008;15:1027-39. (Pubitemid 351953912)
38. Bentzen SM. Theragnostic imaging for radiation oncology: dose-painting by numbers. Lancet Oncol 2005;6:112-7. (Pubitemid 40197705)
39. Zelhof B, Pickles M, Liney G, et al. Correlation of diffusion-weighted magnetic resonance data with cellularity in prostate cancer. BJUint,doi:doi:10.1111/j.1464-410X.2008.08130.x 2008.
40. Weidner N. Intratumor microvessel density as a prognostic factor in cancer. Am J Physiol 1995;147:9-19.